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osting by EAbstract Endothelium-derived nitric oxide (NO) is synthesized from L-arginine by endothelial
nitric oxide synthase (eNOS) encoded by the NOS3 gene on chromosome7. Since reduced NO syn-
thesis has been implicated in the development of coronary atherosclerosis; polymorphisms of NOS
gene might be associated with increased susceptibility to coronary artery disease (CAD). We there-
fore undertook this study to determine the association between the occurrence of CAD and eNOS4
b/a polymorphism in South Indian patients. We investigated the polymorphisms in the 27 base-pair
tandem repeats in intron4 of the eNOS gene in 100 unrelated CAD patients with positive coronary
angiograms and 100 age and sex matched control subjects without any history of symptomatic
CAD. The eNOS gene intron4 b/a VNTR polymorphism was analyzed by polymerase chain reac-
tion. The plasma lipids levels and other risk factors were also determined. The genotype frequencies
for eNOS4b/b, eNOS4a/b and eNOS4a/a were 63, 26 and 11 per cent in CAD subjects, and 72, 20
and 8 per cent in control subjects, respectively. The genotype frequencies did not differ signiﬁcantly
between the two groups. The frequency of the a allele was 0.24 per cent in CAD subjects and 0.18
per cent in control subjects and no signiﬁcant association was found between patients and control
group (P = 0.57, Odds ratio = 3.62). Plasma lipids, glucose and creatinine levels were signiﬁcantly
increased in CAD group. The genotypic frequencies and the allele frequency did not differ signiﬁ-
cantly between the CAD patients and controls indicating that this polymorphism was not an inde-
pendent risk factor for the development of CAD in South Indian patients.
ª 2010 King Saud University. All rights reserved.(R. Syed).
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lsevier1. Introduction
Millions of people under the age of 40 years across the world
suffer asymptomatically from early coronary artery disease
(CAD), which in many cases leads to heart attacks in later life.
Hence it is important to look for biomarkers in early detection
of CAD. Coronary risk factors, such as hypertension, hyper-
cholesterolemia and diabetes mellitus are also known to cause
210 R. Syed et al.this disorder (Stehbens, 1990). Atherosclerosis is a systemic
dysfunctional endothelial, chronic inﬂammatory, ﬁbroprolifer-
tive, angiogenic, prothrombotic, multifactorial disease of the
arterial intima caused by the retention of modiﬁed low density
lipoproteins, hemodynamic stress, and accelerated by redox
stress (Hayden, 2001; Hayden and Tyagi, 1998, 2000, 2002).
Researchers are now looking to pinpoint a gene or marker that
can help predict the occurrence of CAD and identify indi-
viduals who are at an increased risk. Vascular endothelium
modulates blood vessel wall and homeostasis through the pro-
duction of factors regulating vessel tone, coagulation state, cell
growth, cell death and leukocyte trafﬁcking. One of the most
important endothelial cell products is nitric oxide (NO), which
is the most powerful endogenous vasodilator ever known. It
can inhibit the adhesion, aggregation and recruitment of plate-
lets; vascular smooth muscle cells migration and growth, also
regulates some vessel-platelet interactions and limits the oxida-
tion of atherogenic low density lipoproteins. Nitric oxide (NO)
is synthesized from L-arginine and molecular oxygen by a fam-
ily of three enzymes, the nitric oxide synthase (NOS) (Furcho-
gott, 1990). The constitutive endothelial NO synthase (eNOS)
is expressed in the endothelium, encoded by a 26 exon gene
(NOS3) located on chromosome 7q35 to 36 with a total size
of 21 kb and encodes an mRNA of 4052 nucleotides. Several
allelic variants of eNOS gene have been identiﬁed and their
association with human diseases states has been studied. The
evidence suggest that NO may inhibit several key steps in the
atherosclerosis process and that an alteration in NO produc-
tion within the vascular endothelium could contribute to path-
ogenesis of CAD. Emerging evidence suggests that coronary
artery disease (CAD) is related to defects in the generation
or action of NO. NO released from cells rapidly autooxidizes
to yield NO2, which interacts with hemoglobin to yield NO3
(Ignarro et al., 1993). Because NO2 + NO3 (termed NOx) is
relatively stable in blood, the concentration of NOx in blood
may be an indicator of the endogenous formation of NO.
There are at least three isoenzymes of NOS: inducible NOS,
constitutive neuronal NOS, and constitutive endothelial NOS
(ecNOS), which constitute a ‘‘gene family’’, located on differ-
ent chromosomes and expressed in different cell lines. Several
eNOS gene polymorphisms have been reported as ‘susceptibil-
ity genes’ in various cardiovascular and pulmonary diseases
Marsden et al. (1993). GT substitution in exon7 in codon
298 (Yashimura et al., 1998), T786 mutation in the 5 ﬂanking
region (Yashimura et al., 2000) and high numbers of CA,
which have been repeated in intron 13 of eNOS gene are also
known to be associated with excess of risk of CAD (Stangl
et al., 2000). Among the reported polymorphisms of the eNOS
gene, a signiﬁcant association of the 4b/a polymorphism in
intron 4 of the eNOS gene with coronary artery disease
(CAD) and hypertension has also been reported. Wang et al.
(1996) detected an association between homozygosity for the
eNOS4a allele and an increased risk for CAD in current or
ex-smokers. However, others did not detect a link between this
gene variation and cardiovascular events (Ichihara et al., 1998;
Park et al., 2000; Matyar et al., 2005). Reports say that the var-
iable number of tandem repeat (VNTR) polymorphism located
in intron 4 of eNOS (eNOS4b/a polymorphism) were signiﬁ-
cantly associated with plasma NOx concentration Wang
et al. (1997). In repeats of a 27-bp consensus sequence, two al-
leles, a common large allele and a smaller allele, were explored.
The larger allele (eNOS4b allele), designated ‘b-insertion’ hasﬁve tandem repeats, and the smaller allele (eNOS4a allele)
‘a-deletion’ has four repeats. We investigated this association
between the occurrence of CAD and the intron4 b/a polymor-
phism in South Indian Populations.2. Materials and methods
2.1. Selection criteria
One hundred patients who were angiographically diagnosed as
CAD patients (79males and 21females) consecutively admitted
to the hospital with proven CAD (more than 50% stenosis
affecting at least one vessel) were included in the study. The
controls were those who came to the hospital with pain in
the chest but did not have a history of angina pectoris or
MI, and they showed a normal electrocardiogram (62 males
and 38 females), in whom angiographic examination excluded
the presence of CAD.
All the patients and controls were interviewed and epidemi-
ological data/demographic data was recorded in a structured
questionnaire, that included smoking habits, hypertension,
diabetes, dyslipidemia, diet, occupation, treatment and any
family history of CAD.
2.2. Data on risk factors
For CAD risk factors, the following deﬁnitions were used: sub-
jects were deﬁned as hypertensive if their blood pressure was
>140/90 mm Hg or if they were receiving any antihypertensive
treatment; those with a history of diabetes or who were receiv-
ing any anti diabetic drugs were considered to be diabetic;
those with a total plasma cholesterol concentration of >200
mg/dl or a triglyceride concentration of >180 mg/dl, or who
were receiving lipid lowering drugs, were considered dyslipi-
demic. Smoking history was recorded as either none or current
smokers. A positive family history was the presence of a ﬁrst
degree relative with coronary artery disease at the age of
55years for men and <60years for women.
2.3. Protocol Approval
The institutional review boards of Bhagwan Mahavir Hospital
and Research centre approved the research protocol. Informed
consent was obtained from all patients and controls, as re-
quired by the hospital ethics committee, for clinical and genetic
studies.
2.4. Angiographic study
All patients underwent coronary angiography. Coronary ste-
nosis was considered signiﬁcant in the presence of a luminal
diameter narrowing of >50% of at least one pericardial coro-
nary artery. The severity of coronary artery disease was ex-
pressed by the number of affected vessels (one, two, or three
vessel) and also by means of the Duke scoring system––a prog-
nostic index that includes the number of diseased major ves-
sels, the presence of left main coronary artery disease, the
percentage narrowing of the major vessels, and involvement
of the left anterior descending coronary artery particularly
when the proximal segment shows severe stenosis (>95%).
Table 3 Distribution of VNTR of eNOS genotypes and allelic
frequency of the study population.
Study group VNTR genotype Allelic frequency
N= 100 4b/b 4b/a 4a/a Total b a Total
Table 1 Demographic characteristics of patients and controls.
Cases n= 100 Controls n= 100 p-Value
Age males (21–82) 57.21 ± 14.05 54.32 ± 24 0.81
Age females (20–72) 51.69 ± 11.12 50.62 ± 10.72 0.67
Alcoholics (%) 26 10 <0.01
Diabetics (%) 41 13 <0.001
Hypertension (%) 34 10 <0.01
Smokers (%) 37 8 <0.001
Values are represented as mean ± SD: p< 0.05 in comparison to
control group.
Table 2 Biochemical characteristics of patients and controls.
Parameters (mg/dl) Cases n= 100 Control n= 100 p-Value
Total cholesterol 223.69 ± 62.32 203.34 ± 23.12 0.67
Triglycerides 203.34 ± 85.6 153.41 ± 17.81 <0.0001
HDL-C 45.56 ± 13.95 41.16 ± 10.16 0.15
LDL-C 151.81 ± 63.08 130.12 ± 51.09 0.03
CHO/HDL-C 5.18 ± 2.29 5.34 ± 1.17 0.45
LDL-C/HDL-C 4.03 ± 2.14 3.18 ± 2.16 <0.01
FBS 213.15 ± 118.21 124.72 ± 6.80 <0.0001
Urea 39.19 ± 14.10 35.18 ± 7.83 0.72
Creatinine 1.16 ± 0.95 1.12 ± 0.98 0.75
Values are represented as mean ± SD: p< 0.05 in comparison to
control group.
Correlation and Identiﬁcation of Variable numberof Tandem repeats of eNOS Gene in Coronary arteryThe Duke score ranges from 0 to 100 (0 = no disease,
100 = the most severe disease).
2.5. Biochemical analysis
Blood samples (5 ml) were collected from all subjects after 12 h
of fasting. Blood sample (2 ml) was placed in EDTA tubes for
DNA isolation and 3 ml was used for serum collection.
The serum concentrations of triglycerides (TG), total cho-
lesterol, LDL cholesterol (LDL-C) and HDL cholesterol
(HDL-C), urea, creatinine, fasting blood sugar (FBS), were
measured by the standard methods Auto-analyzer (Chem-
well-USA) used in the clinical laboratory of the hospital at
the time of diagnosis of the patients.
2.6. Analysis of VNTR eNOS gene polymorphisms
Extraction of DNA: genomic DNA was extracted from whole
blood using standard phenol/chloroform methodologies with
ethanol precipitation. The VNTR b/a genotype were identiﬁed
by PCR ampliﬁcation (21). The primer sequences used for
ampliﬁcation were:
5-AGGCCCTATGGTAGTGCCTT-3 (forward primer)
5-TCTCTTAGTGCTGTGGTCAC-3 (reverse primer)
The ﬁnal concentration of the PCR mixture had 1.5 mM
MgCl2, 50 mM KCl, 10 mM Tris–HCl (pH 8.8), 0.1% gelatin,
1% Triton X-100, 0.3 mM each of dNTPs, and 2U Taq DNA
(Bioserve, Hyderabad) polymerase in each reaction tube.
Ampliﬁcation was carried out in a thermo cycler (TAKA-
RA-China) under the following conditions with some changes
in Salami et al. (2006): initial denaturation at 94 C for 5 min,
followed by 35 cycles of denaturation at 94 C for 30 s, anneal-
ing at 58 C for 1 min, extension at 72 C for 1 min and ﬁnal
extension at 72 C for 10 min. The products were separated
on a 1.5% agarose gel and visualized by ethidium bromide
staining.
2.7. Statistical analysis
All statistical analyses were performed with Sigma Stat. V 3.0.
Allele frequencies were estimated by the gene counting meth-
od. The frequencies of the alleles and genotypes were com-
pared between patient and control groups by the v2 test
when appropriate Emery (1976). The v2 test was used for devi-
ation of genotype distribution from Hardy–Weinberg equilib-
rium. The differences between groups were examined by v2 test
or an independent student t-test whichever was appropriate.
The odds ratio (OR) and 95% conﬁdence interval (CI) were
also estimated. We performed multivariate logistic regression
analysis to adjust risk factors, in which CAD was a dependent
variable and independent variables were TG, total cholesterol
level, LDL-C, HDL-C, LDL-C/HDL-C, urea, FBS, createnine
and eNOS genotype.Patients 63 26 11 100 152 (0.76) 48 (0.24) 200
Control 72 20 8 100 164 (0.82) 36 (0.18) 200
v2 = 1.33(2df), p= 0.24 for genotype; v2 = 3.26 (1df), p= 0.057
for allelic frequency.
Odds ratio for b/a genotype, a/a genotype and a allele are 0.83
(95% CI; 0.6–1.13), 0.81 (95% CI; 0.53–1.23), and 0.62 (95% CI;
0.62–0.99) respectively.3. Results
Base line demographics are present in Tables 1 and 2. The
mean age at sampling of patients was 57.21 and 54.32years
in control group. Two alleles of the VNTR in the human
eNOS gene were observed one with four 27 bp repeats (eNO-S4a allele) giving rise to a PCR product of 393 bp, whereas the
other contained ﬁve of such repeats (eNOS4b allele), yielding a
PCR product of 420. The genotype frequencies of 4b/b poly-
morphism in control subjects were 72%, 20% for b/a and
8% for a/a. On the other hand in CAD patients genotype fre-
quencies were 63% for b/b, 26% for b/a and 11% for a/a
(Table 3). There was no signiﬁcant difference in the genotype
of eNOS (v2 = 1.33, P = 0.24, odds ratio = 0.83) between
the cases and controls. The frequencies of the a and b alleles
were 24% and 76% for CAD patients and; 18 and 82% for
the control subjects, respectively which was insigniﬁcant
(v2 = 3.62, P = 0.057, odds ratio = 0.62).
As expected, both the control and patient group showed
differences in the biochemical markers and other conventional
risk factors for CAD. Dyslipidaemia, hypertension, diabetes
mellitus, triglycerides and a previous record of CAD in the
family are much higher in CAD patients than in controls. In
average, LDL was also higher in the CAD group as well as
212 R. Syed et al.total cholesterol. We found that the biochemical parameters
like triglycerides, LDL, glycemia, CAD history, smoking ha-
bit, dyslipidaemia to be independently related to CAD.4. Discussion
Prevention of CAD and reduction of its mortality and morbid-
ity remains one of the greatest public health challenges
throughout the world. Over the last two decades, function of
the vascular endothelium has emerged as a strong marker for
monitoring cardiovascular (CV) health on the basis that
impairment of endothelial function is the earliest event in the
process of developing CAD. Endothelial dysfunction has been
frequently associated with all common CV risk factors predis-
posing to atherosclerosis (Bergholm et al., 2003), such as age
(Celermajer et al., 1994), obesity (Steinberg et al., 1996), hyper-
tension (Linder et al., 1990), hypercholesterolemia (Heitzer
et al., 1996), diabetes (Meigs et al., 2006), smoking (Celermajer
et al., 1996) and physical inactivity (Franzoni et al., 2005).
In the presence of endothelial dysfunction, improvement in
the endothelial function has been observed with various phar-
macological treatments and also was evident with behavioral
modiﬁcations including increased physical activity. Over the
last decade, a remarkable burst of evidence has accumulated;
offering the new perspective that NO plays a pivotal role in
CAD. Even though nitric oxide may not be the only answer,
but it was declared THE MOLECULE OF THE YEAR in
1998 and the discoverers were awarded Noble prize for its role
in cardiovascular diseases. Nitric oxide is a highly diffusible
and versatile molecule that affects almost every biological sys-
tem. Increase in cGMP activates the protein kinase G family,
thus resulting in a cascade of responses at the transcriptional
and translational levels. Increased cGMP causes relaxation
of vascular smooth muscle, mediates shear stress-induced
endothelial dependent vasodilation, inhibits platelet aggrega-
tion, monocyte adhesion to the endothelium, inhibits vascular
smooth muscle cell (VSMC) growth and migration, and ﬁnally,
reduces the oxidation of LDL cholesterol. Recent studies have
found much evidence for the role of oxidative stress in the deg-
radation of NO. This reduction in vascular NO bioavailability
has been shown to contribute to altered vasomotor tone,
hypertension, endothelial dysfunction and development of ath-
erosclerosis (Patel et al., 2000; Bloodsworth et al., 2000). It has
been reported that different VNTR alleles of the eNOS gene
may be associated with CAD and hyperlipidemia (Moreel
et al., 1992; Cavalli et al., 2000). Some investigators identiﬁed
an association of the 27-bp tandem repeat polymorphism with
the risk of MI, CAD and EH (essential hypertension) (Shoji
et al., 2000; Gardemann et al., 2002), whereas others did not
detect any link between CAD, MI and EH (Hibi et al.,
1998). eNOS intron4 a/b polymorphism was found to be a risk
factor in addition to HT, DM, male gender, age and smoking
for the development of CAD in Southern Turkey. Patients
with endothelial nitric oxide synthase (eNOS) intron4 27-bp re-
peat homozygotes were more likely to develop severe coronary
stenosis when they smoked Wang and Wang (2000).
Studies in Indians population show lack of association of
intron4 VNTR of eNOS gene with DR (dilated retinopathy)
in Southern India (Uthra et al., 2007). Venkata et al. (2005)
found strong association of eNOS with RFLP and also studies
from Delhi also confers association of eNOS gene with COPD.Interestingly, the association of ApoB100 VNTR and RFLPs
with plasma lipid concentration or coronary artery disease var-
ies in different ethnic groups and has not always been found to
be associated with CAD.
There was no statistically signiﬁcant difference in eNOS b/a
allele percentages between cases and controls. In fact, discrep-
ancies in association studies may also result from consider-
ation limited to only one polymorphism rather than
combinations of polymorphisms. However, it does emphasize
the importance of such studies, which may help in future to
delineate the high-risk group for CAD, and may be of use in
the genetic screening of patients with CAD belonging to differ-
ent populations.
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